Enovis (ENOV) Stock Price, News & Analysis

Company Overview

Enovis Corporation is a global medical technology company focused on advancing musculoskeletal health. Formerly the surgical and orthopedics segment of Colfax Corporation, Enovis adopted its current name in late 2021 and trades on the New York Stock Exchange under the ticker ENOV. Headquartered in Wilmington, Delaware, the company designs, develops and manufactures a broad portfolio of products intended to improve outcomes for patients with orthopedic, podiatric and wound care needs.

The company’s main business activities span surgical and non‐surgical solutions. Enovis offers joint reconstruction implants, foot and ankle reconstruction devices, and minimally invasive surgical instruments that enable orthopedic surgeons to perform complex procedures with greater precision. In addition, the company markets rehabilitation aids, bracing and support systems, compression therapy products and advanced wound care dressings. Its product suite also includes ultrasound‐based surgical systems and pain management devices designed for postoperative recovery.

With operations in North America, Europe, Asia and select emerging markets, Enovis serves hospitals, outpatient centers, rehabilitation facilities and independent distributors. The company maintains manufacturing sites and R&D centers across multiple continents, enabling it to tailor product development to regional clinical practices and regulatory requirements. Enovis has built a global distribution network that supports direct sales teams as well as partnerships with healthcare providers and third‐party distributors.

Under the leadership of CEO Richard Furlong and CFO Daniel Oates, Enovis has pursued strategic acquisitions—including DJO Global in 2019 and Misonix in 2020—to broaden its product offerings and technological capabilities. Since its rebrand, the company has continued to invest in innovation, targeting enhanced patient mobility and comfort through new material sciences and digital therapy solutions. Enovis remains committed to advancing clinical care by expanding its footprint and introducing differentiated products in the musculoskeletal market.

Key Stats

• Today's Range: $34.00 to $35.40
• 50-Day Range: $29.62 to $37.43
• 52-Week Range: $28.83 to $49.83
• Volume: 992,363 shs
• Average Volume: 902,265 shs
• Market Capitalization: $1.94 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $55.60
• Consensus Rating: Moderate Buy

Enovis Stock Analysis - MarketRank™

Enovis scored higher than 56% of companies evaluated by MarketBeat, and ranked 464th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Enovis has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Enovis has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 14.34%

Earnings Growth

Earnings for Enovis are expected to grow by 14.34% in the coming year, from $2.79 to $3.19 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Enovis is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Enovis is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Enovis has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.18% of the float of Enovis has been sold short.

Short Interest Ratio / Days to Cover

Enovis has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in Enovis has recently increased by 29.15%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Enovis does not currently pay a dividend.

Dividend Growth

Enovis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

14.18% of the float of Enovis has been sold short.

Short Interest Ratio / Days to Cover

Enovis has a short interest ratio ("days to cover") of 6.2.

Change versus previous month

Short interest in Enovis has recently increased by 29.15%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.60

News Sentiment

Enovis has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Enovis this week, compared to 6 articles on an average week.

Search Interest

1 people have searched for ENOV on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Enovis insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.70% of the stock of Enovis is held by insiders.

Percentage Held by Institutions

98.45% of the stock of Enovis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ENOV Stock Analysis - Frequently Asked Questions

How have ENOV shares performed this year?

Enovis' stock was trading at $43.88 at the beginning of 2025. Since then, ENOV stock has decreased by 22.4% and is now trading at $34.03.

How were Enovis' earnings last quarter?

Enovis Corporation (NYSE:ENOV) announced its quarterly earnings data on Thursday, May, 8th. The company reported $0.81 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.07. Enovis's revenue for the quarter was up 8.2% compared to the same quarter last year.
Read the conference call transcript.

Who are Enovis' major shareholders?

Enovis' top institutional shareholders include Wedge Capital Management L L P NC (0.29%), Confluence Investment Management LLC (0.12%), Central Valley Advisors LLC (0.10%) and Fiduciary Financial Group LLC (0.02%). Insiders that own company stock include Matthew L Trerotola, Daniel A Pryor, Brady Shirley, Christopher M Hix, A Clayton Perfall, Phillip Benjamin (Ben) Berry, Patricia A Lang, Bradley J Tandy, Rajiv Vinnakota and John Kleckner.
View institutional ownership trends.

How do I buy shares of Enovis?

Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Enovis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Enovis investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:ENOV
• CIK: 1420800
• Web: www.enovis.com
• Phone: 302-252-9160
• Fax: 301-323-9001
• Employees: 7,367
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Enovis: $55.60
• High Price Target: $70.00
• Low Price Target: $46.00
• Potential Upside/Downside: +63.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($13.95)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 12.20
• P/E Growth: N/A
• Net Income: -$825.49 million
• Net Margins: -37.65%
• Pretax Margin: -37.25%
• Return on Equity: 5.99%
• Return on Assets: 3.44%

Debt

• Debt-to-Equity Ratio: 0.52
• Current Ratio: 2.55
• Quick Ratio: 1.32

Sales & Book Value

• Annual Sales: $2.11 billion
• Price / Sales: 0.92
• Cash Flow: $18.20 per share
• Price / Cash Flow: 1.87
• Book Value: $45.10 per share
• Price / Book: 0.75

Miscellaneous

• Outstanding Shares: 57,120,000
• Free Float: 55,581,000
• Market Cap: $1.94 billion
• Optionable: Optionable
• Beta: 1.70